Skip Navigation Links
 تاریخ های مهم 
 Pre Registered 
 برنامه همایش 
 Personal page 
                             دومین ويژه نامه همايش بهاره چشم پزشكي منتشر شد        شب بهاری چشم پزشکی با رحیم شهریاری       دومین همایش بهاره چشم پزشکی
Skip Navigation Links
        مکان برگزاری
        تاریخ های مهم
        ثبت نام
        ثبت نام شدگان
        برنامه همایش
        صفحه شخصی
        جستجوی سخنران
مقاله Abstract

Title: Safety and Bioavailability of Complete and Half Dose Intravitreal Ziv-Aflibercept Injection in an Experimental Model: Contralateral Eye Study
Author(s): Alireza Lashay MD; Elham Delrish PhD; Elham Ashrafi PhD; Mojtaba Abrishami MD
Presentation Type: Oral
Subject: Retina and Retinal Cell Biology
Presenting Author:
Name: Mojtaba Abrishami
Affiliation :(optional) Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran
E mail:
Phone: 05138433192
Mobile: 09129377278

To evaluate the safety and bioavailability of intravitreal ziv-aflibercept (IVZ) in experimental model.


Thirty–two eyes of 16 male rabbits received one IVZ injection under anesthesia and the operating microscope. All right and left eyes respectively received 1250 and 626 µg/0.05ml of ziv-aflibercept. Then, rabbits were randomly allocated to four groups (4 rabbits in each group) at 24, 168, 336, and 720 hours. The rabbits were euthanized at predesignate intervals and the eyes were enucleated. Indirect ophthalmoscopy, vitreous sampling and electrophysiological recordings were obtained before euthanization. Histological examination was performed after enucleation. Vitreous samples were evaluated by enzyme-linked immunosorbent assay (ELISA) to measure the concentration of aflibercept.


No serious drug-related ocular inflammation and toxicity or systemic adverse events were identified. ERG findings showed no difference to the baseline measurements. Remained vitreal concentration of ziv-aflibercept injection for the 626 µg/ml group were 416, 349, 124, 41.2, and 18.1 (±10 µg/ml ) and for the 1250 ( µg/ml ) group were 833, 737, 284, 87.3, and 38.2 (± 10 µg/ml ), at 0, 24, 168, 336, and 720 hours after injection respectively. The vitreous concentration of aflibercept was analyzed by one-compartment model. The area under curve from time 0 to the end point (AUC last) was 147637.2 hours × µg/ml for the full dose group (1250 µg/0.05ml ) and 68498.4 hours × µg/ml for the half dose group (625 µg/0.05ml ). The assessed vitreous half-life (T 1/2) of ziv-aflibercept was 113 hours in both groups.


IVZ at concentrations of 1250 and 625 µg/0.05mL proved to be safe in the experimental model. It seems that IVZ may be well tolerated. These short-term results suggest that intravitreal ziv-aflibercept could be a cost effective therapeutic option for the treatment of retinal vascular diseases. However,the long-term safety and efficacy of intravitreal ziv-aflibercept remain unknown.


Last News

  - دومین ويژه نامه همايش بهاره چشم پزشكي منتشر شد
  -  شب بهاری چشم پزشکی با رحیم شهریاری
  - دومین همایش بهاره چشم پزشکی